Afferent Pharma Raises $23 Million
Afferent Pharmaceuticals, a Palo Alto, Calif.-based developer of drugs for chronic pain, has raised $23 million in Series A funding. Third Rock Ventures and Pappas Ventures co-led the round, and were joined by Domain Associates and New Leaf Venture Partners. In related news, Afferent has licensed a chronic pain program from Roche.
16 December 2009•7 mins read
